Last reviewed · How we verify
Syndeio Biosciences, Inc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Chiesi Farmaceutici S.p.A. · 1 shared drug class
- Chong Kun Dang Pharmaceutical · 1 shared drug class
- Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
- Mylan Inc. · 1 shared drug class
- Pfizer · 1 shared drug class
- Takeda · 1 shared drug class
- Teva Branded Pharmaceutical Products R&D, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Syndeio Biosciences, Inc:
- Syndeio Biosciences, Inc pipeline updates — RSS
- Syndeio Biosciences, Inc pipeline updates — Atom
- Syndeio Biosciences, Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Syndeio Biosciences, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/syndeio-biosciences-inc. Accessed 2026-05-16.